NeOnc Technologies NTHI 深 沪
等待开盘 09-26 09:30:00 美东时间
3.31
+0.010
+0.30%
华盛通- 最 高3.5199
- 今 开3.36
- 成交量 13.54万股
- 最 低 3.25
- 昨 收 3.30
- 总市值 9.53万
- 52周最高 12.99
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 2.955
- 委 比 84.62%
- 总股本 2.88万
- 历史最高 25.00
- 量 比 0.68
- 振 幅 8.18%
- 历史最低 2.955
- 每 手 1
- 风险率 2.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Roth Capital Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20
Roth Capital analyst Jonathan Aschoff initiates coverage on NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy rating and announces Price Target of $20.
09-25 02:14
NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier
NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing in brain cancer research, focusing on glioblastoma, one of the most aggressive adult brain cancers. Their NEO100 drug uses an intranasal delivery method to bypass the blood-brain barrier, targeting IDH1-mutant tumors. A Phase 2a trial showed promising results: 48.9% progression-free survival at six months and a median overall survival of 26.09 months, with minimal toxicities. NeOnc plans to ...
09-22 18:52
NeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc Technologies Holdings' NEO100, a nasal spray formulation of perillyl alcohol, shows promise in treating recurrent high-grade glioma, targeting the blood-brain barrier challenge. Phase 2a results demonstrate a 48.9% six-month progression-free survival vs. a 20% benchmark, with median overall survival of 26.09 months. NEO100's intranasal delivery aims to bypass the blood-brain barrier via the olfactory pathway, offering a potential non-invasi...
09-21 12:00
NeOnc Technologies redeems all $6M Series A preferred stock
NeOnc Technologies (NTHI) said on Thursday that it had redeemed all 6,000 outstanding Series A preferred shares for $6M. The redemption was funded with part of the proceeds from the company's $15M reg...
09-17 20:59
NeOnc CEO Boosts Stake After Recent Offering
NeOnc Technologies Holdings, Inc. ( ($NTHI) ) has shared an announcement. On Se...
09-17 18:29
NeOnc Announces Executive Chairman, President And CEO Amir Heshmatpour Purchases Additional 35K Of Company Shares For ~$115,400, At Weighted Average Price Of ~$3.30/Shr
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour...
09-16 20:04
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
NeOnc Technologies Holdings (NASDAQ: NTHI) has seen significant insider buying, with CEO Amir F. Heshmatpour purchasing 37,000 shares at $3.6654 each, following a $15 million registered direct offering at $4.20 per share. This purchase, along with other insider investments, highlights confidence in the company's prospects. NeOnc recently reported promising Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma, showing a 48.9% six...
09-14 13:07
NeOnc Technologies Enters $15M Securities Purchase Agreements In At‑The‑Market Offering
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and ex...
09-09 20:05
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
